electroCore Announces Poster to be Presented at the American Headache Society’s 65th Annual Scientific Meeting
June 13 2023 - 8:00AM
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic
medicine and wellness company, announced today that “SUNCT/ SUNA
with neurovascular conflict: consider nVNS,” will be presented at
the American Headache Society’s 65th Annual Scientific Meeting on
June 16-17, 2023 in Austin, Texas.
The abstract and poster highlight the observed efficacy of nVNS
in three patients with rare headache diseases, SUNCT/SUNA, in
the class of headache disorders known as Trigeminal Autonomic
Cephalalgia’s (“TACs”). The retrospective study suggests that nVNS,
as a treatment for TACs in general, and specifically for refractory
SUNCT/ SUNA, should be considered before microvascular
neurosurgery, particularly given the well-recognized risks and
costs of such surgical procedures.
Poster Presentation Details:Title: SUNCT/SUNA
with neurovascular conflict: consider nVNSDate: Saturday, June 17,
2023Time: 12:45 pm ETPresenter: Dr. María Dolores Villar-Martínez,
King’s College London
About electroCore, Inc.electroCore, Inc. is a
commercial stage bioelectronic medicine and wellness company
dedicated to improving health through its non-invasive vagus nerve
stimulation (“nVNS”) technology platform. Our focus is the
commercialization of medical devices for the management and
treatment of certain medical conditions and consumer product
offerings utilizing nVNS to promote general wellbeing and human
performance in the United States and select overseas markets.
For more information, visit www.electrocore.com.
Forward-Looking StatementsThis press release
and other written and oral statements made by representatives of
electroCore may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Such forward-looking statements include, but are not limited to,
statements about electroCore's business prospects and clinical and
product development plans (including with respect to ongoing
studies); its pipeline or potential markets for its technologies;
the timing, outcome and impact of regulatory, clinical and
commercial developments; the issuance of U.S. and international
patents providing expanded IP coverage; the possibility of future
business models and revenue streams from the company’s potential
use of nVNS for rare TAC’s in general and SUNCT/SUNA in particular,
the potential of nVNS generally and gammaCore in particular and
other statements that are not historical in nature, particularly
those that utilize terminology such as "anticipates," "will,"
"expects," "believes," "intends," other words of similar meaning,
derivations of such words and the use of future dates. Actual
results could differ from those projected in any forward-looking
statements due to numerous factors. Such factors include, among
others, the ability to raise the additional funding needed to
continue to pursue electroCore’s business and product development
plans, the inherent uncertainties associated with developing new
products or technologies, the ability to commercialize gammaCore™,
the potential impact and effects of COVID-19 on the business of
electroCore, electroCore’s results of operations and financial
performance, and any measures electroCore has and may take in
response to COVID-19 and any expectations electroCore may have with
respect thereto, competition in the industry in which electroCore
operates and overall market conditions. Any forward-looking
statements are made as of the date of this press release, and
electroCore assumes no obligation to update the forward-looking
statements or to update the reasons why actual results could differ
from those projected in the forward-looking statements, except as
required by law. Investors should consult all of the information
set forth herein and should also refer to the risk factor
disclosure set forth in the reports and other documents electroCore
files with the SEC available at www.sec.gov.
Contact:ECOR Investor Relations(973)
302-9253investors@electrocore.com
electroCore (NASDAQ:ECOR)
Historical Stock Chart
From Jul 2024 to Jul 2024
electroCore (NASDAQ:ECOR)
Historical Stock Chart
From Jul 2023 to Jul 2024